Nuformix plc (LON:NFX – Get Free Report)’s stock price fell 9.7% on Monday . The stock traded as low as GBX 0.14 ($0.00) and last traded at GBX 0.14 ($0.00). 2,727,746 shares were traded during trading, a decline of 15% from the average session volume of 3,191,435 shares. The stock had previously closed at GBX 0.16 ($0.00).
Nuformix Stock Performance
The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The firm’s fifty day moving average price is GBX 0.17 and its two-hundred day moving average price is GBX 0.19. The stock has a market capitalization of £1.15 million, a PE ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Further Reading
- Five stocks we like better than Nuformix
- Where to Find Earnings Call Transcripts
- Why Block’s Key Components Make It a Solid Investment Choice
- 10 Best Airline Stocks to Buy
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
